PCN47 Value of Driver Mutation Testing Strategies based on Next-Generation Sequencing (NGS) for Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC)

Abstract

Treatment for mNSCLC is driven by the presence of oncogenic genomic mutations. Establishing histological subtype with tissue biopsy and identification of mutations via tissue next-generation sequencing (NGS) can guide treatment decisions. Adding Plasma NGS to Tissue NGS (Tissue NGS Reflex-to-Plasma NGS) can help in identifying appropriate patients when tissue biopsy may not be feasible. This study compares Tissue NGS Reflex-to-Plasma NGS versus Tissue NGS-Only strategies for identifying patients with mNSCLC with actionable mutations.